Biomarker ID | 1474 |
PMID | 25075204 |
Year | 2014 |
Biomarker | SMAD4 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.48 |
Effect on Pathways | Pathways include: Cell cycle: G1/S checkpoint, NF-kappaB activation by non-typeable Hemophilus influenzae, TGF-beta receptor activation of SMADs, Heart development, CTCF pathway |
Experiment | Lethal Outcome Vs No Lethal Outcome |
Type of Biomarker | Prognostic |
Cohort | 340 Prosteactomy samples were chosen in the cohort and divided into training and testing |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.0035 |
Method Used | Automated quantitative multiplex immunofluorescence in situ imaging |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |